AGRX Agile Therapeutics, Inc.

3.46
-0.02  -1%
Previous Close 3.48
Open 3.49
Price To book 2.81
Market Cap 99.67M
Shares 28,806,000
Volume 141,338
Short Ratio 6.26
Av. Daily Volume 270,710

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued 2013. Phase 3 top-line data released January 3, 2017 - poor data but reconfirmed April 11, 2017 its intention to reflile NDA 2Q 2017.
Twirla
Contraceptive patch

Latest News

  1. AGRX: Initiating Coverage of Agile Therapeutics; NDA for Weekly Contraceptive Patch Set to Be Filed…
  2. Agile Therapeutics reports 1Q loss
  3. Agile Therapeutics Reports First Quarter 2017 Financial Results
  4. Agile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla® at ACOG 2017
  5. Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists
  6. Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women’s Health
  7. Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA
  8. Agile Therapeutics (AGRX) Catches Eye: Stock Moves Up 14%
  9. Agile Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
  10. IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  11. DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Agile Therapeutics, Inc. (AGRX) & Lead Plaintiff Deadline - March 7, 2017
  12. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agile Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – AGRX
  13. UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Agile Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 7, 2017
  14. EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Agile Therapeutics, Inc. - AGRX
  15. Agile Therapeutics to Present at 29th Annual ROTH Conference
  16. DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Agile Therapeutics, Inc. (AGRX) and Lead Plaintiff Deadline - March 7, 2017
  17. IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  18. DEADLINE ALERT: Brower Piven Reminds Investors Of The March 7, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Agile Therapeutics, Inc. To Contact The Firm
  19. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

SEC Filings

  1. S-8 - Securities to be offered to employees in employee benefit plans 17827345
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17822714
  3. 8-K - Current report 17822430
  4. 8-K - Current report 17805469
  5. DEF 14A - Other definitive proxy statements 17778580
  6. 8-K - Current report 17764851
  7. 8-K - Current report 17756229
  8. 8-K - Current report 17695041
  9. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17691737
  10. 8-K - Current report 17675373